导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 20.65% | 378/4773 |
| 近一周 | 0.93% | 549/5465 |
| 近一月 | -4.73% | 3426/5421 |
| 近一季 | -10.66% | 3797/5231 |
| 近半年 | 16.33% | 362/4920 |
| 近一年 | 22.07% | 424/4394 |
| 近两年 | 139.26% | 316/2954 |
| 近三年 | 94.63% | 190/2253 |
| 成立以来 | 64.91% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.94% 3974/4961 |
71.44% 253/5312 |
- - |
- - |
| 2025 | 38.02% 877/4813 |
2.77% 1268/3635 |
-0.18% 2833/4076 |
43.13% 664/4524 |
-6.00% 3656/4813 |
| 2024 | 18.42% 606/3463 |
-6.97% 2099/2808 |
-0.58% 791/3014 |
15.19% 1793/3129 |
11.15% 234/3463 |
| 2023 | 2.69% 307/2656 |
24.27% 104/2280 |
-6.50% 1655/2385 |
-10.14% 1963/2515 |
-1.64% 350/2655 |
| 2022 | -31.41% 1656/2207 |
-22.24% 1689/1919 |
-0.64% 1642/2016 |
-15.89% 1364/2113 |
5.54% 459/2208 |
| 2021 | 8.33% 481/1822 |
-9.45% 1107/1255 |
17.63% 181/1330 |
-6.83% 995/1466 |
9.15% 126/1822 |
| 2020 | 19.78% 729/1250 |
-0.82% 193/1028 |
22.50% 205/1067 |
-0.08% 1050/1164 |
-1.33% 1102/1184 |
| 2019 | 52.54% 89/1092 |
41.01% 45/754 |
-10.13% 716/804 |
10.86% 45/850 |
8.58% 303/918 |
| 2018 | -31.37% 494/834 |
- - |
- - |
- - |
-12.34% 436/691 |
| 2017 | 0.24% 480/714 |
- - |
- - |
- - |
- - |
| 2016 | -24.72% 477/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发信息技术联接A VS. 长安沪深300非周期A(740101) |